210 related articles for article (PubMed ID: 9749581)
1. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis.
Beal MF
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S110-4. PubMed ID: 9749581
[TBL] [Abstract][Full Text] [Related]
2. Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T
Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201
[TBL] [Abstract][Full Text] [Related]
3. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases.
Schulz JB; Matthews RT; Klockgether T; Dichgans J; Beal MF
Mol Cell Biochem; 1997 Sep; 174(1-2):193-7. PubMed ID: 9309687
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group.
Schapira AH; Mann VM; Cooper JM; Krige D; Jenner PJ; Marsden CD
Ann Neurol; 1992; 32 Suppl():S116-24. PubMed ID: 1510369
[TBL] [Abstract][Full Text] [Related]
5. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
Przedborski S; Jackson-Lewis V; Yokoyama R; Shibata T; Dawson VL; Dawson TM
Proc Natl Acad Sci U S A; 1996 May; 93(10):4565-71. PubMed ID: 8643444
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide and reactive oxygen species in Parkinson's disease.
Tieu K; Ischiropoulos H; Przedborski S
IUBMB Life; 2003 Jun; 55(6):329-35. PubMed ID: 12938735
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.
Watanabe H; Muramatsu Y; Kurosaki R; Michimata M; Matsubara M; Imai Y; Araki T
Eur Neuropsychopharmacol; 2004 Mar; 14(2):93-104. PubMed ID: 15013024
[TBL] [Abstract][Full Text] [Related]
8. Reduction of MPP(+)-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase.
Smith TS; Swerdlow RH; Parker WD; Bennett JP
Neuroreport; 1994 Dec; 5(18):2598-600. PubMed ID: 7535121
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
[TBL] [Abstract][Full Text] [Related]
10. The role of glutamate in the pathophysiology of Parkinson's disease.
Blandini F; Greenamyre JT; Nappi G
Funct Neurol; 1996; 11(1):3-15. PubMed ID: 8936453
[No Abstract] [Full Text] [Related]
11. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity.
Klivenyi P; Andreassen OA; Ferrante RJ; Lancelot E; Reif D; Beal MF
Neuroreport; 2000 Apr; 11(6):1265-8. PubMed ID: 10817604
[TBL] [Abstract][Full Text] [Related]
12. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease.
Ebadi M; Sharma SK
Antioxid Redox Signal; 2003 Jun; 5(3):319-35. PubMed ID: 12880486
[TBL] [Abstract][Full Text] [Related]
13. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase.
Ferrante RJ; Hantraye P; Brouillet E; Beal MF
Brain Res; 1999 Mar; 823(1-2):177-82. PubMed ID: 10095024
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Hantraye P; Brouillet E; Ferrante R; Palfi S; Dolan R; Matthews RT; Beal MF
Nat Med; 1996 Sep; 2(9):1017-21. PubMed ID: 8782460
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial dysfunction in Parkinson's disease.
Greenamyre JT; MacKenzie G; Peng TI; Stephans SE
Biochem Soc Symp; 1999; 66():85-97. PubMed ID: 10989660
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide.
Morale MC; Serra PA; Delogu MR; Migheli R; Rocchitta G; Tirolo C; Caniglia S; Testa N; L'Episcopo F; Gennuso F; Scoto GM; Barden N; Miele E; Desole MS; Marchetti B
FASEB J; 2004 Jan; 18(1):164-6. PubMed ID: 14630699
[TBL] [Abstract][Full Text] [Related]
17. Cerebral alterations in a MPTP-mouse model of Parkinson's disease--an immunocytochemical study.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
J Neural Transm (Vienna); 2003 Oct; 110(10):1129-44. PubMed ID: 14523625
[TBL] [Abstract][Full Text] [Related]
18. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
[TBL] [Abstract][Full Text] [Related]
19. Iron-dependent enzymes in Parkinson's disease.
Reichmann H; Janetzky B; Riederer P
J Neural Transm Suppl; 1995; 46():157-64. PubMed ID: 8821051
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity.
Himeda T; Kadoguchi N; Kamiyama Y; Kato H; Maegawa H; Araki T
Neuropharmacology; 2006 Mar; 50(3):329-44. PubMed ID: 16303147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
